STI-IMT-LMIS4, EPFL, 1015, Lausanne, Switzerland.
Vortex Biosciences, Inc., Pleasanton, California, 94588.
Cytometry A. 2019 Oct;95(10):1085-1095. doi: 10.1002/cyto.a.23868. Epub 2019 Jul 31.
The isolation, analysis, and enumeration of circulating tumor cells (CTCs) from cancer patient blood samples are a paradigm shift for cancer patient diagnosis, prognosis, and treatment monitoring. Most methods used to isolate and enumerate these target cells rely on the expression of cell surface markers, which varies between patients, cancer types, tumors, and stages. Here, we propose a label-free high-throughput platform to isolate, enumerate, and size CTCs on two coupled microfluidic devices. Cancer cells were purified through a Vortex chip and subsequently flowed in-line to an impedance chip, where a pair of electrodes measured fluctuations of an applied electric field generated by cells passing through. A proof-of-concept of the coupling of those two devices was demonstrated with beads and cells. First, the impedance chip was tested as a stand-alone device: (1) with beads (mean counting error of 1.0%, sizing information clearly separated three clusters for 8, 15, and 20 um beads, respectively) as well as (2) with cancer cells (mean counting error of 3.5%). Second, the combined setup was tested with beads, then with cells in phosphate-buffered saline, and finally with cancer cells spiked in healthy blood. Experiments demonstrated that the Vortex HT chip enriched the cancer cells, which then could be counted and differentiated from smaller blood cells by the impedance chip based on size information. Further discrimination was shown with dual high-frequency measurements using electric opacity, highlighting the potential application of this combined setup for a fully integrated label-free isolation and enumeration of CTCs from cancer patient samples. © 2019 International Society for Advancement of Cytometry.
从癌症患者的血液样本中分离、分析和计数循环肿瘤细胞(CTCs)是癌症患者诊断、预后和治疗监测的范式转变。大多数用于分离和计数这些靶细胞的方法都依赖于细胞表面标志物的表达,而这些标志物在患者、癌症类型、肿瘤和分期之间存在差异。在这里,我们提出了一种无标记的高通量平台,用于在两个耦合的微流控设备上分离、计数和测量 CTCs 的大小。癌细胞通过涡流芯片进行纯化,然后在线流动到阻抗芯片,其中一对电极测量细胞通过时产生的施加电场的波动。通过珠子和细胞证明了这两个设备的耦合的概念验证。首先,阻抗芯片作为独立的设备进行了测试:(1)使用珠子(计数误差平均为 1.0%,大小信息清楚地将 8、15 和 20 μm 的珠子分别分为三个簇),以及(2)使用癌细胞(计数误差平均为 3.5%)。其次,使用珠子、磷酸盐缓冲盐水中的细胞以及健康血液中混入的癌细胞测试了组合设置。实验表明,Vortex HT 芯片富集了癌细胞,然后阻抗芯片可以根据大小信息对其进行计数并与较小的血细胞区分开来。使用双高频测量进行电不透明度的进一步区分,突出了这种组合设置在从癌症患者样本中完全集成的无标记分离和计数 CTCs 方面的潜在应用。© 2019 国际细胞分析促进协会。